ArticleNaunyn-Schmiedeberg's archives of pharmacology2014
Evaluation of commercial antibodies against human sphingosine-1-phosphate receptor 1.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 12 citations in OpenAlex.
- Article
- Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor.British journal of pharmacology · 2018Article
- Commercially available antibodies directed against α-adrenergic receptor subtypes and other G protein-coupled receptors with acceptable selectivity in flow cytometry experiments.Naunyn-Schmiedeberg's archives of pharmacology · 2016Article
- Rat β₃-adrenoceptor protein expression: antibody validation and distribution in rat gastrointestinal and urogenital tissues.Naunyn-Schmiedeberg's archives of pharmacology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosine-1-phosphate receptor 1 (S1P1), also called endothelial differentiation gene 1, plays an important role in migration, proliferation, and survival of several types of cells including endothelial cells and lymphocytes and is involved in multiple sclerosis. Two commercial rabbit anti-S1P1 antibodies (polyclonal and monoclonal) were tested on CHO cells expressing S1P1 receptors fused to the green fluorescent protein at the C-terminal end and on Pichia pastoris and HEK cells expressing cmyc-tagged S1P1. Polyclonal antibodies did not give any signal by Western blot, immunofluorescence, and flow cytofluorometry. Monoclonal antibodies were able to reveal an unspecific band by Western blot performed on various cell types. Consequently, in our hands and using our protocols, we show that these antibodies did not specifically detect S1P1 receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.